论文部分内容阅读
At 13 years of follow-up,the European Randomized Study of Screening for Prostate Cancer shows a 21%decrease in prostate cancer deaths in the prostate-specific antigenscreened group compared to control.This difference increases to 27%when non compliance is taken into account.The benefits of screening compared to control are higher at 28%(compared to 21%)when duration of follow-up ranges between 8 and 12 years.Such data obtained following an average rate of one screening performed once every 5.7 years in quite impressive and strongly supports the use of screening for a successful fight against a cancer which grows to an advanced and non curable stage without any specific sign or symptom.
At 13 years of follow-up, the European Randomized Study of Screening for Prostate Cancer shows a 21% decrease in prostate cancer deaths in the prostate-specific antigens creened group compared to control. This difference increases to 27% when non compliance is taken into account .The benefits of screening compared to control are higher at 28% (compared to 21%) when duration of follow-up ranges between 8 and 12 years.Such data obtained the following an average rate of one screening performed once every 5.7 years in quite and strongly supports the use of screening for a successful fight against a cancer which grows to an advanced and non curable part without any specific sign or symptom.